An FGFR1-Binding Peptide Modified Liposome for siRNA Delivery in Lung Cancer

Liposome modification by targeting ligands has been used to mediate specific interactions and drug delivery to target cells. In this study, a new peptide ligand, CP7, was found to be able to effectively bind to FGFR1 through reverse molecular docking and could cooperate with VEGFR3 to achieve target...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-08, Vol.23 (15), p.8380
Main Authors: Dong, Zhipeng, Yin, Yunxue, Luo, Jun, Li, Bingxia, Lou, Fangning, Wang, Qiyan, Zhou, Qingfa, Ye, Baofen, Wang, Yue
Format: Article
Language:English
Subjects:
Angiogenesis
Antitumor activity
Apoptosis
Binding
Binding sites
Bioavailability
Biocompatibility
Cancer therapies
Cell cycle
Drug delivery
Drug delivery systems
Drugs
Fibroblast growth factor receptor 1
Gene therapy
Gene transfer
Genetic engineering
Hydrogen bonds
Leukemia
Ligands
Liposomes
Lung cancer
Mcl-1 protein
Molecular docking
Peptides
Proteins
siRNA
Software
Tumor cells
Vascular endothelial growth factor receptors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liposome modification by targeting ligands has been used to mediate specific interactions and drug delivery to target cells. In this study, a new peptide ligand, CP7, was found to be able to effectively bind to FGFR1 through reverse molecular docking and could cooperate with VEGFR3 to achieve targeting of A549 cells. CP7 was modified on the surface of the liposome to construct a targeted and safe nanovehicle for the delivery of a therapeutic gene, Mcl-1 siRNA. Due to the specific binding between CP7 and A549 cells, siRNA-loaded liposome-PEG-CP7 showed increased cellular uptake in vitro, resulting in significant apoptosis of tumor cells through silencing of the Mcl-1 gene, which is associated with apoptosis and angiogenesis. This gene delivery system also showed significantly better antitumor activity in tumor-bearing mice in vivo. All of these suggested that siRNA-loaded liposome-PEG-CP7 could be a promising gene drug delivery system with good bioavailability and minimal side effects for treatment.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23158380